U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT06969001) titled 'Clinical Study for the Evaluation of Safety and Tolerability of SCAI-005 Eye Drops' on April 28.
Brief Summary: To assess the single-dose and multiple-dose pharmacokinetics (PK), safety and tolerability of SCAI-005 eyedrops(axitinib) in healthy volunteers
Study Start Date: May 27
Study Type: INTERVENTIONAL
Condition:
Wet Age Related Macular Degeneration
Intervention:
DRUG: SCAI-005 0.04% or placebo
axitinib 0.014mg or placebo
DRUG: SCAI-005 0.08% or placebo
axitinib 0.028mg or placebo
DRUG: SCAI-005 0.08% or placebo 2drops
axitinib 0.056mg or placebo
Recruitment Status: NOT_YET_RECRUITING
Sponsor: SCAI Therapeutics
Publ...